Tuomas Jussi Lumikari1, Jani Pirinen2, Jukka Putaala1, Gerli Sibolt1, Anne Kerola3, Sami Pakarinen4, Mika Lehto5, Tuomo Nieminen3. 1. Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. 2. Department of Clinical Physiology and Nuclear Medicine, HUS Diagnostics, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. 3. Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland. 4. Department of Internal Medicine, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. 5. Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
Abstract
BACKGROUND: Paroxysmal atrial fibrillation (pAF) is a major risk factor for ischemic stroke, but challenging to detect with routine short-term monitoring methods. In this pilot study, we present a novel method for prolonged ECG and screening for pAF in patients with a recent embolic stroke of unknown source (ESUS). METHODS: Fifteen patients aged ≥ 50 years with a recent ESUS were assigned to wear an external electrode belt-based 1-lead ECG device (Beat2Phone) continuously for 2 weeks (wear time). The device was operated via a mobile phone application in nonhospital conditions. The primary outcome was patient adherence to monitoring. Secondary outcomes were incidence of new pAF, quality-wise comparison to Holter, and usability of the novel ECG monitoring method with Systems Usability Scale (SUS). We also performed a 24- to 48-hr comparison between simultaneous Beat2Phone ECG and a standard Holter in 6 patients. RESULTS: Wear time of Beat2Phone device was over 80% in 5 (33.3%) patients, 50%-80% in 7 (46.6%) patients, and less than 50% in 3 (20%) patients. We detected pAF ≥ 30 s in 1 patient (6.7%). In the simultaneous monitoring with Beat2Phone and Holter, there were a total of 817 (out of 1979) analyzable periods of sinus rhythm or premature atrial or ventricular beats (Cohen's Kappa coefficient 0.92 ± 0.02 between Beat2Phone and Holter), and no pAF events. Beat2Phone ECG showed remarkable SUS scores in user evaluations (average score: 81.4 out of 100 on SUS). CONCLUSIONS: Beat2Phone device was easy to use among ESUS patients and in optimal conditions provided high-quality 1-lead ECG signal for diagnosing pAF. CLINICAL TRIAL REGISTRATION: The study was not registered, as it was a nonrandomized single-arm pilot study.
BACKGROUND:Paroxysmal atrial fibrillation (pAF) is a major risk factor for ischemic stroke, but challenging to detect with routine short-term monitoring methods. In this pilot study, we present a novel method for prolonged ECG and screening for pAF in patients with a recent embolic stroke of unknown source (ESUS). METHODS: Fifteen patients aged ≥ 50 years with a recent ESUS were assigned to wear an external electrode belt-based 1-lead ECG device (Beat2Phone) continuously for 2 weeks (wear time). The device was operated via a mobile phone application in nonhospital conditions. The primary outcome was patient adherence to monitoring. Secondary outcomes were incidence of new pAF, quality-wise comparison to Holter, and usability of the novel ECG monitoring method with Systems Usability Scale (SUS). We also performed a 24- to 48-hr comparison between simultaneous Beat2Phone ECG and a standard Holter in 6 patients. RESULTS: Wear time of Beat2Phone device was over 80% in 5 (33.3%) patients, 50%-80% in 7 (46.6%) patients, and less than 50% in 3 (20%) patients. We detected pAF ≥ 30 s in 1 patient (6.7%). In the simultaneous monitoring with Beat2Phone and Holter, there were a total of 817 (out of 1979) analyzable periods of sinus rhythm or premature atrial or ventricular beats (Cohen's Kappa coefficient 0.92 ± 0.02 between Beat2Phone and Holter), and no pAF events. Beat2Phone ECG showed remarkable SUS scores in user evaluations (average score: 81.4 out of 100 on SUS). CONCLUSIONS: Beat2Phone device was easy to use among ESUS patients and in optimal conditions provided high-quality 1-lead ECG signal for diagnosing pAF. CLINICAL TRIAL REGISTRATION: The study was not registered, as it was a nonrandomized single-arm pilot study.
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas Journal: Eur Heart J Date: 2016-08-27 Impact factor: 29.983
Authors: Jonathan P Piccini; Susanna R Stevens; YuChiao Chang; Daniel E Singer; Yuliya Lokhnygina; Alan S Go; Manesh R Patel; Kenneth W Mahaffey; Jonathan L Halperin; Günter Breithardt; Graeme J Hankey; Werner Hacke; Richard C Becker; Christopher C Nessel; Keith A A Fox; Robert M Califf Journal: Circulation Date: 2012-12-03 Impact factor: 29.690
Authors: Jukka Putaala; Tuomo Nieminen; Elena Haapaniemi; Atte Meretoja; Kirsi Rantanen; Noora Heikkinen; Janne Kinnunen; Daniel Strbian; Satu Mustanoja; Sami Curtze; Sami Pakarinen; Mika Lehto; Turgut Tatlisumak Journal: Ann Med Date: 2015-08-04 Impact factor: 4.709
Authors: José Manuel Rubio Campal; M Araceli García Torres; Pepa Sánchez Borque; Inmaculada Navas Vinagre; Ivana Zamarbide Capdepón; Ángel Miracle Blanco; Loreto Bravo Calero; Rafael Sáez Pinel; José Tuñón Fernández; José María Serratosa Fernández Journal: Am J Cardiol Date: 2019-11-06 Impact factor: 2.778
Authors: Tuomas J Lumikari; Jukka Putaala; Anne Kerola; Gerli Sibolt; Jani Pirinen; Sami Pakarinen; Mika Lehto; Tuomo Nieminen Journal: Ann Noninvasive Electrocardiol Date: 2019-05-02 Impact factor: 1.468
Authors: Tuomas Jussi Lumikari; Jani Pirinen; Jukka Putaala; Gerli Sibolt; Anne Kerola; Sami Pakarinen; Mika Lehto; Tuomo Nieminen Journal: Ann Noninvasive Electrocardiol Date: 2020-09-27 Impact factor: 1.468
Authors: Marta Leńska-Mieciek; Aleksandra Kuls-Oszmaniec; Natalia Dociak; Marcin Kowalewski; Krzysztof Sarwiński; Andrzej Osiecki; Urszula Fiszer Journal: J Clin Med Date: 2022-01-27 Impact factor: 4.241